LBA21 FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group

Bond, Marinde J G; Bolhuis, Karen; Loosveld, Olaf; Droogendijk, Helga J.; Groot, J.W.B. de; Hendriks, Mathijs P.; Valk, B. De; Liem, Mike S L; Rijken, Arjen M.; Verhoef, Kees; Wilt, Johannes H. W. de; Jong, Koert P. de; Kazemier, Geert; Amerongen, Martinus J. van; Engelbrecht, Marc R.; Klaase, Joost M.; Komurcu, Aysun; Lopez-Yurda, Martha; Swijnenburg, R-J.; Punt, Cornelis J.A.

doi:10.1016/j.annonc.2022.08.017

Cited by 10 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients were selected from the CAIRO5 study (NCT02162563), a randomised phase III trial of the DCCG, comparing the currently most effective systemic induction regimens in patients with initially unresectable colorectal cancer liver-only metastases. 14 – 16 Patients randomised between the start of the study in November 2014 and April 2021 were selected for this subset analysis. The CAIRO5 study was conducted in accordance with the standards of Good Clinical Practice and the Declaration of Helsinki.…”

Section: Methodsmentioning

confidence: 99%

Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases: Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group

Bond¹,

Kuiper²,

Bolhuis³

et al. 2023

Ann Surg Oncol

View full text Add to dashboard Cite

Background Consensus on resectability criteria for colorectal cancer liver metastases (CRLM) is lacking, resulting in differences in therapeutic strategies. This study evaluated variability of resectability assessments and local treatment plans for patients with initially unresectable CRLM by the liver expert panel from the randomised phase III CAIRO5 study. Methods The liver panel, comprising surgeons and radiologists, evaluated resectability by predefined criteria at baseline and 2-monthly thereafter. If surgeons judged CRLM as resectable, detailed local treatment plans were provided. The panel chair determined the conclusion of resectability status and local treatment advice, and forwarded it to local surgeons. Results A total of 1149 panel evaluations of 496 patients were included. Intersurgeon disagreement was observed in 50% of evaluations and was lower at baseline than follow-up (36% vs. 60%, p < 0.001). Among surgeons in general, votes for resectable CRLM at baseline and follow-up ranged between 0–12% and 27–62%, and for permanently unresectable CRLM between 3–40% and 6–47%, respectively. Surgeons proposed different local treatment plans in 77% of patients. The most pronounced intersurgeon differences concerned the advice to proceed with hemihepatectomy versus parenchymal-preserving approaches. Eighty-four percent of patients judged by the panel as having resectable CRLM indeed received local treatment. Local surgeons followed the technical plan proposed by the panel in 40% of patients. Conclusion Considerable variability exists among expert liver surgeons in assessing resectability and local treatment planning of initially unresectable CRLM. This stresses the value of panel-based decisions, and the need for consensus guidelines on resectability criteria and technical approach to prevent unwarranted variability in clinical practice.

show abstract

Section: Methodsmentioning

confidence: 99%

Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases: Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group

Bond¹,

Kuiper²,

Bolhuis³

et al. 2023

Ann Surg Oncol

View full text Add to dashboard Cite

show abstract

“…8 At the ESMO Congress 2022, data from patients with left-sided and RAS/BRAF V600E wild-type primary tumors were reported. 7 At a median follow-up of 44 months, there was no difference in median PFS between the bevacizumab (n=114) and panitumumab (n=116) arms (10.8 months vs 10.4 months, HR: 1.12 [95% CI: 0.83-1.52]; p=0.45). Panitumumab versus bevacizumab plus chemotherapy improved ORRs (76% vs 52%; p<0.001) and depth of response (49% vs 33%; p<0.001); however, this did not translate into a higher resection/ablation rate (67% vs 68%; p=1).…”

Section: Pd Dr Sara De Dosso Deputy Head Of Medical Oncologymentioning

confidence: 88%

“…Furthermore, patients with left-sided and RAS/BRAF V600E wild-type primary tumors were randomized to receive doublet chemotherapy plus either bevacizumab (anti-vascular endothelial growth factor [VEGF] antibody) or panitumumab (anti-epidermal growth factor receptor [EGFR] antibody). 7,8 The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), overall response rate (ORR), toxicity, R0/1 resection rates and postoperative morbidity. Results from patients with right-sided and/or RAS/BRAF V600E-mutated primary tumors were presented at the ASCO Annual Meeting 2022 and showed a clinical benefit of the triplet combination regimen in this patient population.…”

Section: Pd Dr Sara De Dosso Deputy Head Of Medical Oncologymentioning

confidence: 99%

Advances in Colon Cancer Therapy

2022

healthbook TIMES Onco Hema

View full text Add to dashboard Cite

Neoadjuvant therapy in colon cancerNeoadjuvant therapy in the management colon cancer is an underdeveloped field 1 and surgical resection followed by adjuvant chemotherapy is currently the only treatment option available to Swiss Neoadjuvant therapies have shown many positive impacts in upper gastrointestinal these benefits could be potentially translated in colon cancer such as the early treatment of systemic micro-metastases, downsizing of tumors by increasing R0 resection, as well as testing the response to treatment on an individual basis.

show abstract

“…The CAIRO5 study [ 5 ], a multicenter, randomized, phase III trial presented at ESMO in 2022, enrolled patients with CRCLMs and carried out genetic testing to identify RAS and BRAF mutational status. This clinical study primarily presented the results of patients with left‐sided and wild‐type RAS/BRAFV600E tumors who were randomized to be treated with chemotherapy plus either bevacizumab (arm A) or panitumumab (arm B), with a median follow‐up of 44 months.…”

Section: Chemotherapy For Crcmentioning

confidence: 99%

Advances and prospects of drug clinical research in colorectal cancer in 2022

Liu

Cui

et al. 2023

Cancer Innovation

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer death worldwide. Clinical research results have provided more treatment opportunities for CRC patients, showing that an optimal combination of existing drugs and new drugs is needed to mitigate the burden of this disease. In this review, we have summarized recent advances in drug clinical research for CRC in 2022, including chemotherapy, targeted therapy, and immunotherapy, to find opportunities for substantial improvements in drug discovery and clinical development methods.

show abstract

LBA21 FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group

Cited by 10 publications

References 0 publications

Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases: Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group

Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases: Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group

Advances in Colon Cancer Therapy

Advances and prospects of drug clinical research in colorectal cancer in 2022

Contact Info

Product

Resources

About